Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report) and keeping the price target at $118.00.
Larry Biegelsen has given his Buy rating due to a combination of factors including Boston Scientific’s strong financial performance and positive future outlook. The company reported first-quarter revenue and earnings per share that exceeded market expectations, driven by robust growth in its PFA and Watchman product lines. Despite facing a significant tariff impact in 2025, Boston Scientific has raised its organic growth and earnings guidance for the year, indicating confidence in its ability to maintain momentum.
Additionally, the company has demonstrated strong operational efficiency, with gross and operating margins surpassing estimates. The transition in the CFO position is expected to be smooth, given the successor’s extensive experience within the company. Boston Scientific’s strategic initiatives and market position suggest continued growth, supporting the Buy rating. The company’s ability to navigate challenges such as tariffs while still projecting strong growth further underscores the positive outlook.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $124.00 price target.
BSX’s price has also changed moderately for the past six months – from $87.450 to $98.920, which is a 13.12% increase.